Prognosis of hepatitis B virus reactivation in newly diagnosed multiple myeloma in modern era therapy: a retrospective study

Studies on the prognosis of hepatitis B virus (HBV) reactivation following modern therapies for newly diagnosed MM (NDMM) are lacking. In this retrospective study, we aimed to assess the incidence, risk factors and prognosis of HBV reactivation in NDMM. A total of 33 of 355 patients with NDMM and HB...

Full description

Saved in:
Bibliographic Details
Published inPeerJ (San Francisco, CA) Vol. 12; p. e18475
Main Authors Lv, Weiran, Li, Xiaojin, Xu, Jingbo, Wang, Yun, Huang, Hanying, Hu, Fang, Cui, Yingying, Song, Yuanbin, Chen, Lezong, Wu, Bingyi, Liang, Yang
Format Journal Article
LanguageEnglish
Published United States PeerJ. Ltd 01.11.2024
PeerJ Inc
Subjects
Adult
Aged
Bortezomib - therapeutic use
Female
Gastroenterology and Hepatology
Health aspects
Hematology
Hepatitis B - drug therapy
Hepatitis B - virology
Hepatitis B Surface Antigens - blood
Hepatitis B virus
Hepatitis B virus - physiology
Humans
Infectious Diseases
Male
Middle Aged
Multiple myeloma
Multiple Myeloma - drug therapy
Multiple Myeloma - mortality
Multiple Myeloma - therapy
Multiple Myeloma - virology
Oncology
Prevention
Prognosis
Reactivation
Retrospective Studies
Risk Factors
Statistics
Virology
Virus Activation
China
Reactivation
Prognosis
Hepatitis B virus
Multiple myeloma
Online AccessGet full text

Cover

More Information
Summary:Studies on the prognosis of hepatitis B virus (HBV) reactivation following modern therapies for newly diagnosed MM (NDMM) are lacking. In this retrospective study, we aimed to assess the incidence, risk factors and prognosis of HBV reactivation in NDMM. A total of 33 of 355 patients with NDMM and HBV reactivation were included in this study. Multivariable analysis showed that hepatitis B surface antigen-positivity, hepatitis B core antibody-positivity, bortezomib-containing regimens, autologous stem cell transplantation, and gain of 1q21 were identified as independent risk factors of HBV reactivation in NDMM patients. The NDMM patients with HBV reactivation had poorer 3-year overall survival (OS) and progression-free survival (PFS) than did those without HBV reactivation, as confirmed by multivariate analysis. In conclusion, HBV reactivation in patients with NDMM constitutes a significant complication, correlating with reduced OS and PFS, and emerges as a potential adverse prognostic factor in the contemporary era of treatment.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2167-8359
2167-8359
DOI:10.7717/peerj.18475